Target intelligence / Profile preview

Solute carrier organic anion transporter family member 1B1, 1B3, and 2B1 (OATP1B1/1B3/2B1)

Target
OATP1B1/1B3/2B1
Molecular classification
Transporter, Solute carrier family, SLCO family
01

Overview

The organic anion-transporting polypeptides OATP1B1, OATP1B3, and OATP2B1 are key uptake transporters located on the basolateral (sinusoidal) membrane of human hepatocytes. They belong to the solute carrier (SLC) superfamily and are responsible for the sodium-independent transport of a broad range of endogenous and exogenous organic anions from the blood into the liver. Endogenous substrates include bile acids, bilirubin, and various hormones, while exogenous substrates encompass many widely used drugs such as statins, antihypertensives, and chemotherapeutic agents. Genetic polymorphisms, particularly in the SLCO1B1 gene, or pharmacological inhibition of these transporters can lead to significantly increased systemic drug concentrations, increasing the risk of adverse effects like statin-induced myopathy. Consequently, they are critical targets for evaluating drug-drug interactions during pharmaceutical development and are subject to specific regulatory guidelines from agencies like the FDA and EMA.

Other names
Organic anion-transporting polypeptide 1B1Organic anion-transporting polypeptide 1B3Organic anion-transporting polypeptide 2B1SLCO1B1SLCO1B3SLCO2B1OATP-COATP-2OATP-8OATP-BLST-1LST-2LST-3
02

Mechanism of action

These proteins function as uptake transporters that facilitate the entry of organic anions into hepatocytes; drugs can act as substrates for transport or as inhibitors that block the uptake of other compounds.

03

Biological functions

Hepatic uptake of organic anionsBile acid transportBilirubin transportHormone transportXenobiotic transportEnterohepatic circulation
04

Disease associations

HyperbilirubinemiaRotor syndromeStatin-induced myopathyRhabdomyolysisCancerDrug-induced liver injury
05

Safety considerations

Drug-drug interactions (DDIs)Statin-induced myopathyRhabdomyolysisHyperbilirubinemiaIncreased systemic drug exposure due to genetic polymorphisms (e.g., SLCO1B1*5)
06

Interacting drugs

Atorvastatin

13 more in the full profile.

07

Biomarkers

Coproporphyrin I (CP-I)Coproporphyrin III (CP-III)BilirubinEstrone-3-sulfate

Beyond the preview

Go deeper on Solute carrier organic anion transporter family member 1B1, 1B3, and 2B1 (OATP1B1/1B3/2B1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier organic anion transporter family member 1B1, 1B3, and 2B1 (OATP1B1/1B3/2B1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call